To identify key factors influencing the effectiveness of platelet-rich plasma (PRP) therapy in treating elbow tendinopathy, a common degenerative condition.
Adults aged 19 years or older
Diagnosed with elbow tendinopathy
Persistent pain despite receiving conservative treatment
Individuals with systemic infection at the time of study participation
Patients with rheumatic diseases or inflammatory disorders
Individuals with unstable systemic conditions affecting the cardiovascular, gastrointestinal, respiratory, or endocrine systems
Any other cases deemed inappropriate for study participation by the investigator
Single group
Autologous Platelet-Rich Plasma (PRP) Injection
Biological/VaccineParticipants will receive autologous PRP injections prepared from their own blood to treat elbow tendinopathy. PRP is a plasma product with a 3-5 times higher platelet concentration than normal blood, containing growth factors such as TGF-β, PDGF, IGF, and EGF, which are known to promote tissue repair and regeneration. The PRP will be injected directly into the affected tendon area to evaluate its clinical effectiveness and the relationship between platelet concentration, growth factors, and treatment outcomes.
Change in Patient-Rated Tennis Elbow Evaluation (PRTEE) Score
The PRTEE is a validated questionnaire used to assess pain and functional disability in patients with elbow tendinopathy. It consists of 15 items divided into pain (5 items) and function (10 items). Scores range from 0 to 100, with higher scores indicating more severe pain and functional impairment. A decrease in score reflects improvement in symptoms.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
